The first Chinese bispecific antibodies ADC declared for clinical use

Hey! This is Weekly Pharma News Review from PharmaVibe. I'm Billy. It's been a long time since our last episode. I hope all of you' re doing well and thank you for joining us today. In the last week's Chinese pharma market, Alphamab Oncology’s JSKN003 injection became the first Chinese bispecific antibody ADC declared for clinical use. While in the global pharma market, AstraZeneca/Daiichi Sankyo, Novartis and Sanofi all provide update on their clinical development programs. You can access the full version on Access the full transcript and more fresh content at www.pharmasources.com and enjoy more firsthand market information in the Chinese and global markets.